Objectives

After participating in this educational activity, attendees should be able to:

1. Explain the mechanism of the immune-checkpoint inhibitor nivolumab
2. Discuss common toxicities associated with immune-checkpoint inhibitors
3. Determine an effective strategy for managing toxicities associated with immune-checkpoint inhibitors
4. Apply this information to a patient case.

Faculty

Taylor Hodle, PharmD 
PGY2 Critical Care Pharmacy Resident
Pharmacist
Baystate Medical Center

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  Faculty or planner conflicts of interest are resolved before the educational activity.

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.